Spyre stock soars as UC drug touts Entyvio-rivalling potential
Spyre Therapeutics’ stock is up nearly 30% after its ulcerative colitis (UC) candidate has demonstrated competitive remission-prompting potential during a …
Post
-
-
Never-married individuals reported to have higher cancer risk
Cancer is the leading cause of death globally, accounting for one in six deaths worldwide in 2020, according to the …
-
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase …
-
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
GSK has shared encouraging data from its Phase I BEHOLD-1 clinical trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting …
-
Preparation is key to understanding global trade compliance for trials
For global studies, investigational material and active pharmaceutical ingredients (API) are often shipped to sites in different countries from a …
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of …
-
OCT Europe 2026: tackling clinical trial complexities with innovation and partnerships
Regulatory changes, geopolitical pressures and technological advancements are among the factors currently driving new and evolving challenges within the clinical …
-
Verastem Oncology’s combo shows two-year durability in ovarian cancer
Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during an …
-
Smartwatches could aid in monitoring heart failure exacerbations
Heart failure (HF) is a substantial global health problem that is characterised by significant mortality and poor quality of life. …
-
ReAlta lands $40m to back trial of first-in-class infant brain injury therapy
ReAlta Life Sciences has secured $40m to back the continuation of a Phase II study of its lead candidate, pegtarazimod, …
-
Sparian commences Phase I trial of SBS-147 for pain treatment
Sparian Biosciences has initiated a Phase I study of SBS-147, an arylepoxamide receptor (AEAr) agonist under development for the treatment …
-
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral pan-rho-associated protein …
-
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents …
-
Takeda’s platelet disorder drug triggers up to 91% response rate
A mid-stage trial on Takeda’s anti-CD38 therapy, mezagitamab, has demonstrated the drug’s potential to boost platelet counts in patients with …
-
Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function
Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of …
